Navigation Links
MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
Date:9/11/2008

GAITHERSBURG, Md. and TOKYO, Sept. 11 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., announced today that they have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. MedImmune has global rights to any resulting product candidates and will be responsible for preclinical and clinical development, as well as all future development, manufacturing, sales and marketing activities.

"It's an honor to work with Ken-ichi Arai, founder of SBI Biotech and one of Japan's leading scientists. We look forward to collaborating with him and his organization as we develop potential new treatments for autoimmune diseases such as SLE," said Anthony J. Coyle, Ph.D., vice president, research, respiratory, inflammation and autoimmunity. "As an innovative company dedicated to making a difference for patients, MedImmune will continue to seek out research and development initiatives that may address some of society's critical unmet medical needs."

Under the terms of the agreement, MedImmune is to provide SBI Biotech with an undisclosed upfront payment, milestone payments and royalties on future marketed products. SBI Biotech has granted MedImmune an exclusive license to research, develop and commercialize products that target the ILT7 protein. In addition, MedImmune will have the option to license additional targets resulting from SBI Biotech's research activities.

"We are pleased to collaborate with MedImmune, a company with strong capabilities to develop therapeutic antibodies including expertise in humanization and large-scale production. MedImmune is an excellent company and this agreement facilitates the research and development of an anti-ILT7 antibody," said Ken-ichi Arai, M.D. and Ph.D., president & CEO, SBI Biotech. "We have been seeking other potential targets for treatments of autoimmune diseases and cancer and will continue further research and development. We are confident that the collaboration with MedImmune will greatly strengthen the potential for our program."

About ILT7

ILT7 is a cell surface protein uniquely expressed on plasmacytoid dendritic cells (pDC). Targeting ILT7 offers potential to treat autoimmune diseases because pDCs are believed to be critical in the development of autoimmune diseases such as systemic lupus erythematosus.

About MedImmune

MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune's website at http://www.medimmune.com.

About SBI Biotech Co., Ltd.

SBI Biotech Co., Ltd, the drug subsidiary company of SBI Holdings, Inc. is conducting its business as the global bioventure company by assembling discovery pipelines from Japan, United States, China and Korea. SBI Biotech advances drug discovery and new therapy by utilizing the global network of SBI researchers, receiving investments from venture capital and by collaborating with pharmaceutical companies and university hospitals. For more information on SBI Biotech, please refer to the company's website at http://www.sbibiotech.jp.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
2. MedImmune Expands Scientific and Engineering Leadership
3. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
4. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
5. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
6. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
7. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
8. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
9. Further Acquisition for Schofield Media Group LLC
10. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
11. Area Women Gather in Milford on July 10 to Further the Mission of Womens Caring Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of traumatic brain ... conduct a survey that takes a closer look at cases of TBI being managed ... causes of TBI among the aging population, and identifies the challenges associated with their ...
(Date:2/10/2016)... MI (PRWEB) , ... February 10, 2016 , ... ... Apifiny® across their network of laboratory service centers across the country. Launched ... to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... announced that it has been awarded the prestigious Distinguished Emerald Club of the ... program conducted by BoardRoom magazine, one of the most respected trade publications serving ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics, who is celebrating ... evolved from humble beginnings to being an internationally recognized leader in their industry. , ... today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the importance of good ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Face and Body Specialists are delighted to welcome a new addition to their ... Face and Body Specialists as a nurse practitioner performing cosmetic procedures ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016 CSI Specialty Group (CSI) expanded ... of the Specialty Pharmacy Podcast. A free, weekly show, ... providing real-world education, discussion and context amongst specialty pharmacy ... --> The Specialty Pharmacy Podcast, hosted ... Specialty Group Suzette DiMascio, CHE, CMCE, CPC, is available ...
(Date:2/10/2016)... Feb. 10, 2016 Immune Pharmaceuticals Inc. (NASDAQ: ... today that it has filed a patent application directed ... cancers. --> --> ... administration of Ceplene (histamine dihydrochloride) in combination with immune ... predicting the efficacy of Ceplene and IL-2 therapy in ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in ... the Grand Challenge to generate a biomarker to track TDP43 ... receive up to a $1 million investment. ... neurodegenerative disease that affects nerve cells in the brain and ... to initiate and control muscle movement, which often leads to ...
Breaking Medicine Technology: